Sight Sciences Management
Management criteria checks 4/4
Sight Sciences' CEO is Paul Badawi, appointed in Jan 2011, has a tenure of 15.5 years. total yearly compensation is $2.01M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 10.19% of the company’s shares, worth $30.22M. The average tenure of the management team and the board of directors is 3.2 years and 6 years respectively.
Key information
Paul Badawi
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 32.86% |
| CEO tenure | 15.5yrs |
| CEO ownership | 10.2% |
| Management average tenure | 3.2yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Narrative Update • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.
Narrative Update • Jun 17
SGHT: Sector Support And Dry Eye Execution Will Drive Future Upside
Analysts have increased their price target on Sight Sciences stock to $5.15 from $4.35, citing refreshed medical technology sector models after Q1 updates and a view that broader fundamentals in the space remain solid. Analyst Commentary on Sight Sciences Recent research commentary on Sight Sciences centers on refreshed models following Q1 updates and a reassessment of where the stock fits within the broader medical technology group.Narrative Update • Jun 02
SGHT: Dry Eye Execution And TearCare Adoption Will Support Future Upside
Analysts have maintained Sight Sciences' fair value target at $12.00 while refining underlying assumptions such as discount rate and margin forecasts. Recent Street research highlights sector models being refreshed and mixed segment trends as key drivers of the updated $5.15 Citi price target and other revised targets across the stock.Narrative Update • May 10
SGHT: Weaker Glaucoma Trends Will Limit Rerating Despite Solid Dry Eye Momentum
Analysts have trimmed their price targets for Sight Sciences, with one key target moving from $6.50 to $5 and another from $12 to $11. These revisions reflect updated views on a mix of steady sector fundamentals, solid Dry Eye performance, and softer Surgical Glaucoma trends.Narrative Update • Apr 23
SGHT: Dry Eye Franchise And TearCare Adoption Will Drive Future Upside
The blended analyst price target for Sight Sciences has moved modestly lower to $11 from $12, as analysts balance pressure in Surgical Glaucoma against steady TearCare adoption, sector wide target resets, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research updates show a wide range of views on Sight Sciences, with price targets clustered between the mid single digits and low double digits and ratings spanning Neutral to Buy.Narrative Update • Apr 08
SGHT: TearCare And Dry Eye Adoption Will Support Future Upside Potential
Narrative Update on Sight Sciences Analysts have adjusted price targets for Sight Sciences into a range of $5 to $11, reflecting updated views on the balance between softer Surgical Glaucoma trends and stronger TearCare and Dry Eye performance. Overall sector fundamentals are described as healthy.Narrative Update • Mar 25
SGHT: Dry Eye Momentum Will Support Stronger Outlook Than Surgical Glaucoma
Analysts have trimmed their average price target on Sight Sciences by $1.00, reflecting updated assumptions around growth, margins and sector risk after recent research highlighted mixed trends between TearCare strength and softer Surgical Glaucoma performance. Analyst Commentary Street research on Sight Sciences has converged around a more cautious but still constructive stance, with price targets adjusted to reflect mixed trends between TearCare strength and softer Surgical Glaucoma performance.Narrative Update • Mar 11
SGHT: TearCare Momentum Will Support Rerating Despite Surgical Glaucoma Concerns
The updated analyst price target for Sight Sciences moves to $6.50, reflecting a blended view where some analysts trimmed targets, others raised them toward $8 to $11, and recent feedback on TearCare and mixed segment trends shaped modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Sight Sciences gives you a mixed picture, with some analysts more constructive on TearCare adoption and others turning more cautious on execution and growth in the surgical glaucoma segment.Narrative Update • Feb 24
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have maintained their $12.00 price target on Sight Sciences, noting that minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions largely offset one another. What's in the News Sight Sciences issued new earnings guidance for the fourth quarter of 2025, with total revenue expected between $20.3 million and $20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Key Developments).Narrative Update • Feb 09
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have kept their price target for Sight Sciences steady at US$12.00, citing updated assumptions that include slightly higher discount and P/E expectations, along with adjusted revenue growth and profit margin forecasts. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue projected between US$20.3 million and US$20.4 million.Narrative Update • Jan 26
SGHT: Fair Outlook Balances Guidance Revision With Leadership And Margin Assumptions
Analysts have lifted their price target for Sight Sciences from US$3.60 to US$6.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple as key drivers of the change. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue expected between US$20.3 million and US$20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Corporate Guidance).Analysis Article • Jan 21
Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge Could Signal Some Risk
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has softened a substantial 26% over the previous 30 days, handing...
Narrative Update • Jan 11
SGHT: Final Medicare Coverage Will Support Dry Eye Upside Potential
Analysts have lifted their price target on Sight Sciences from $7.85 to $9.35, citing recent Medicare coverage decisions for the TearCare dry eye disease treatment system as a key support for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the finalized Medicare coverage policies for TearCare as a key support for the higher price targets, since clearer reimbursement can make revenue visibility easier to model.Seeking Alpha • Dec 31
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Summary Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances. SGHT faces significant liquidity risks, and I believe the company should look to raise cash in 2026, particularly in light of the recent share price surge. I see fair value near $9.50/share, but further upside depends on sales execution and additional coverage wins. Read the full article on Seeking AlphaNarrative Update • Dec 26
SGHT: Medicare Coverage Expansion Will Drive Stronger Outlook For Dry Eye Therapy
Analysts have raised their price target on Sight Sciences from $5 to $7 per share, citing recently finalized Medicare coverage policies for the TearCare dry eye treatment system as a key potential driver of outperformance. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in Sight Sciences' ability to monetize new Medicare coverage for its TearCare dry eye treatment system.Narrative Update • Dec 11
SGHT: Final Medicare Coverage Will Shape Dry Eye Outlook And Execution Risks
Analysts have modestly raised their price target on Sight Sciences from approximately $6.08 to about $7.85 per share, citing improved fair value estimates and expectations that finalized Medicare coverage for the TearCare dry eye treatment system could drive future outperformance. Analyst Commentary With the recent coverage decisions for TearCare by key Medicare administrative contractors, Street research has become more constructive on Sight Sciences' medium term outlook, though some execution risks remain in focus.Narrative Update • Nov 27
SGHT: Broader Medicare Coverage Will Increase Risks For Execution Going Forward
Analysts have raised their price target for Sight Sciences from $5.00 to $7.00 per share. They cite broader Medicare coverage for its Dry Eye Disease treatment system as a key factor supporting the positive outlook.Analysis Article • Nov 13
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Nov 08
SGHT: Higher Medicare Access Will Increase Competitive Execution Risks Ahead
Analysts have raised their price target for Sight Sciences from approximately $4.42 to $5.08, citing expanded Medicare coverage and stronger growth expectations across key financial metrics. Analyst Commentary Bullish Takeaways Bullish analysts highlighted the substantial increase in the price target following newly finalized Medicare coverage for the TearCare system.Analysis Article • Oct 18
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has done very well over the last month, posting an excellent gain...Analysis Article • Aug 09
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
NasdaqGS:SGHT 1 Year Share Price vs Fair Value Explore Sight Sciences's Fair Values from the Community and select yours...Narrative Update • Aug 08
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27. What's in the News Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs.Analysis Article • May 14
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
Sight Sciences, Inc. ( NASDAQ:SGHT ) shareholders would be excited to see that the share price has had a great month...
New Narrative • Apr 04
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.Analysis Article • Mar 30
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Sight Sciences, Inc.'s ( NASDAQ:SGHT ) price-to-sales (or "P/S") ratio of 1.6x might make it look like a buy right now...Analysis Article • Jan 17
Is Sight Sciences (NASDAQ:SGHT) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Nov 13
Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has fared very poorly over the last month, falling by a...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$37m |
| Dec 31 2025 | US$2m | US$659k | -US$38m |
| Sep 30 2025 | n/a | n/a | -US$46m |
| Jun 30 2025 | n/a | n/a | -US$49m |
| Mar 31 2025 | n/a | n/a | -US$49m |
| Dec 31 2024 | US$3m | US$640k | -US$52m |
| Sep 30 2024 | n/a | n/a | -US$50m |
| Jun 30 2024 | n/a | n/a | -US$52m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$4m | US$610k | -US$56m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$71m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$6m | US$580k | -US$86m |
| Sep 30 2022 | n/a | n/a | -US$85m |
| Jun 30 2022 | n/a | n/a | -US$80m |
| Mar 31 2022 | n/a | n/a | -US$74m |
| Dec 31 2021 | US$9m | US$424k | -US$63m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$497k | US$360k | -US$35m |
Compensation vs Market: Paul's total compensation ($USD2.01M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Badawi (50 yo)
15.5yrs
Tenure
US$2,005,608
Compensation
Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.5yrs | US$2.01m | 10.19% $ 30.2m | |
| Chief Operating Officer | less than a year | US$1.63m | 0.31% $ 925.5k | |
| Chief Legal Officer & Corporate Secretary | 6.3yrs | US$974.25k | 0.16% $ 475.6k | |
| Co-Founder | 15.5yrs | no data | 3.32% $ 9.8m | |
| CFO & Treasurer | less than a year | no data | 0.087% $ 257.0k | |
| VP and Chief Ethics & Compliance Officer | 3.2yrs | no data | no data | |
| Executive Vice President of Operations and R&D | 1.7yrs | no data | 0.058% $ 172.4k |
3.2yrs
Average Tenure
47.5yo
Average Age
Experienced Management: SGHT's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.5yrs | US$2.01m | 10.19% $ 30.2m | |
| Co-Founder | 15.5yrs | no data | 3.32% $ 9.8m | |
| Independent Director | 1.3yrs | US$283.62k | 0.17% $ 517.5k | |
| Independent Director | 6yrs | US$202.50k | 0.30% $ 901.2k | |
| Independent Chairman | 8.8yrs | US$231.00k | 3.75% $ 11.1m | |
| Independent Director | 4yrs | US$189.61k | 0.15% $ 443.6k | |
| Independent Director | 3.1yrs | US$197.00k | 0.13% $ 373.0k |
6.0yrs
Average Tenure
61yo
Average Age
Experienced Board: SGHT's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 16:24 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sight Sciences, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |